Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2026—Seegene launched its new antimicrobial resistance testing product, the Allplex MDRO assay. The assay, which is CE marked under the EU in vitro diagnostic regulation, is designed to identify key multidrug-resistant pathogens and associated resistance genes in a single run and can support same-day reporting, depending on laboratory workflow.
July 2026—Sysmex America has introduced the XR-Series, a hematology solution designed to help laboratories deliver fast, reliable results while maintaining efficient workflows. The next-generation XR-Series builds on the capabilities of the XN-Series, adding higher throughput, enhanced analytics, and complementary solutions that aim to streamline daily laboratory operations.
July 2026—Roche introduced the Cobas MPX-E assay, a qualitative in vitro test for the detection and discrimination of HIV 1 and 2 and hepatitis C, B, and E viruses, in countries accepting the CE mark. By identifying these pathogens simultaneously, the assay aims to help laboratories streamline their operations while enhancing the safety of blood and blood products for patients.
July 2026—Tempus AI has launched the ArteraAI Prostate test (mHSPC) for clinical use. The test uses multimodal artificial intelligence to provide insights for personalized care for patients with metastatic hormone-sensitive prostate cancer.
July 2026—Streck has launched MDx-Chex for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis and MDx-Chex for MVP (multiplex vaginal panel) for research use only.
July 2026—QuidelOrtho has completed the acquisition of Lex Diagnostics for about $100 million in cash. The acquisition follows the FDA 510(k) clearance and CLIA waiver of the Lex Velo molecular diagnostics platform in February.
July 2026—CareDx has entered into a definitive agreement to acquire Naveris for $160 million up front plus up to $100 million in additional payments tied to revenue milestones. Naveris is a precision oncology diagnostics company with a Medicare-reimbursed, blood‑based monitoring test for cancers caused by viral infections.
July 2026—Labcorp announced that ColoSense, an FDA-approved, at-home test for colorectal cancer screening, is now available for adults ages 45 to 85 who are at average risk for developing CRC. The test uses RNA-based technology to detect biomarkers associated with colorectal cancer and advanced adenomas.
July 2026—Labcorp and Children’s Hospital of Philadelphia are collaborating to advance the discovery, development, and availability of specialized pediatric diagnostics. CHOP and Labcorp will create a joint pediatric diagnostics innovation pipeline in which the organizations will identify, develop, and expand new tests and technologies, with the aim of streamlining the path from discovery to national availability.
July 2026—Integrated DNA Technologies launched Archer FusionPlex-HT Dx and VariantPlex-HT Dx in vitro diagnostic assay solutions for next-generation sequencing. The products are built on IDT’s proprietary Anchored Multiplex PCR chemistry for targeted DNA and RNA sequencing.
